Cargando…
Antipsychotics cardiotoxicity: What's known and what's next
Chronic use of antipsychotic medications entails a dilemma between the benefit of alleviating psychotic symptoms and the risk of troubling, sometimes life-shortening adverse effects. Antipsychotic-induced cardiotoxicity is one of the most life-threatening adverse effects that raises widespread conce...
Autores principales: | , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Baishideng Publishing Group Inc
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8546771/ https://www.ncbi.nlm.nih.gov/pubmed/34733639 http://dx.doi.org/10.5498/wjp.v11.i10.736 |
_version_ | 1784590256153034752 |
---|---|
author | Li, Xiao-Qing Tang, Xin-Ru Li, Li-Liang |
author_facet | Li, Xiao-Qing Tang, Xin-Ru Li, Li-Liang |
author_sort | Li, Xiao-Qing |
collection | PubMed |
description | Chronic use of antipsychotic medications entails a dilemma between the benefit of alleviating psychotic symptoms and the risk of troubling, sometimes life-shortening adverse effects. Antipsychotic-induced cardiotoxicity is one of the most life-threatening adverse effects that raises widespread concerns. These cardiotoxic effects range from arrhythmia to heart failure in the clinic, with myocarditis/cardiomyopathy, ischemic injuries, and unexplained cardiac lesions as the pathological bases. Multiple mechanisms have been proposed to underlie antipsychotic cardiotoxicity. This review aims to summarize the clinical signs and pathological changes of antipsychotic cardiotoxicity and introduce recent progress in understanding the underlying mechanisms at both the subcellular organelle level and the molecular level. We also provide an up-to-date perspective on future clinical monitoring and therapeutic strategies for antipsychotic cardiotoxicity. We propose that third-generation antipsychotics or drug adjuvant therapy, such as cannabinoid receptor modulators that confer dual benefits — i.e., alleviating cardiotoxicity and improving metabolic disorders — deserve further clinical evaluation and marketing. |
format | Online Article Text |
id | pubmed-8546771 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2021 |
publisher | Baishideng Publishing Group Inc |
record_format | MEDLINE/PubMed |
spelling | pubmed-85467712021-11-02 Antipsychotics cardiotoxicity: What's known and what's next Li, Xiao-Qing Tang, Xin-Ru Li, Li-Liang World J Psychiatry Review Chronic use of antipsychotic medications entails a dilemma between the benefit of alleviating psychotic symptoms and the risk of troubling, sometimes life-shortening adverse effects. Antipsychotic-induced cardiotoxicity is one of the most life-threatening adverse effects that raises widespread concerns. These cardiotoxic effects range from arrhythmia to heart failure in the clinic, with myocarditis/cardiomyopathy, ischemic injuries, and unexplained cardiac lesions as the pathological bases. Multiple mechanisms have been proposed to underlie antipsychotic cardiotoxicity. This review aims to summarize the clinical signs and pathological changes of antipsychotic cardiotoxicity and introduce recent progress in understanding the underlying mechanisms at both the subcellular organelle level and the molecular level. We also provide an up-to-date perspective on future clinical monitoring and therapeutic strategies for antipsychotic cardiotoxicity. We propose that third-generation antipsychotics or drug adjuvant therapy, such as cannabinoid receptor modulators that confer dual benefits — i.e., alleviating cardiotoxicity and improving metabolic disorders — deserve further clinical evaluation and marketing. Baishideng Publishing Group Inc 2021-10-19 /pmc/articles/PMC8546771/ /pubmed/34733639 http://dx.doi.org/10.5498/wjp.v11.i10.736 Text en ©The Author(s) 2021. Published by Baishideng Publishing Group Inc. All rights reserved. https://creativecommons.org/licenses/by-nc/4.0/This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/Licenses/by-nc/4.0/ |
spellingShingle | Review Li, Xiao-Qing Tang, Xin-Ru Li, Li-Liang Antipsychotics cardiotoxicity: What's known and what's next |
title | Antipsychotics cardiotoxicity: What's known and what's next |
title_full | Antipsychotics cardiotoxicity: What's known and what's next |
title_fullStr | Antipsychotics cardiotoxicity: What's known and what's next |
title_full_unstemmed | Antipsychotics cardiotoxicity: What's known and what's next |
title_short | Antipsychotics cardiotoxicity: What's known and what's next |
title_sort | antipsychotics cardiotoxicity: what's known and what's next |
topic | Review |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8546771/ https://www.ncbi.nlm.nih.gov/pubmed/34733639 http://dx.doi.org/10.5498/wjp.v11.i10.736 |
work_keys_str_mv | AT lixiaoqing antipsychoticscardiotoxicitywhatsknownandwhatsnext AT tangxinru antipsychoticscardiotoxicitywhatsknownandwhatsnext AT lililiang antipsychoticscardiotoxicitywhatsknownandwhatsnext |